Stanford researchers have developed easyBAT, a simplified solution integrating a microfluidic sample preparation device with a fully automated analysis pipeline for rapid, accurate and accessible solution for food allergy diagnosis at the point-of-care.
Stanford researchers have developed a new technology, Variant-FlowFISH, to enable high-throughput, highly sensitive measurements of how variants, introduced via CRISPR, affect gene expression.
Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.
Stanford researchers have developed a high-affinity IL-11 decoy cytokine for super-agonism and antagonism of the IL-11 receptor, enabling the treatment of a wide variety of diseases from inflammatory disease to cancer as well as research into IL-11 signaling pathways.
Stanford researchers have developed a pioneering gene therapy by targeting reactive astrocytes in the optic nerve head (ONH) and modulating cyclic adenosine monophosphate (cAMP) levels for targeted treatment of glaucoma and other retinal disorders.
Stanford researchers have developed a new, low-cost method for tumor methylation profiling that enables tumor classification even from low amounts of fragmented DNA characteristic of liquid biopsies.
The Longaker lab at Stanford University has recently discovered that local injection of the drug Verteporfin after wounding can reduce scarring, improve the strength of healed skin, and regrow the hair follicles and sweat glands that are usually lost during the scarring proces
Skin wounds invariably heal by developing fibrotic scar tissue, which can result in devastating disfigurement, growth restriction and permanent functional loss.
Stanford inventors have developed a novel diagnostic tool that identifies distinct immune signatures in the peripheral blood of osteoarthritis patients using mass cytometry (CyTOF) and applied machine learning.
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Stanford scientists develop a method for assessing patient risk of developing postsurgical neurocognitive complications using a combination of biomarkers. This method will ensure improved interventions and treatment outcomes.